Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

October 31, 2016

Conditions
Atrial FibrillationCoronary Artery Disease
Interventions
DRUG

Regadenoson MRI

AF patients will be provided with a regadenoson stress MRI to see if coronary artery disease can be detected with more sensitivity /specificity.

DRUG

Gadobenate dimeglumine

Resting perfusion with Multihance Gd-BOPTA contrast agent will be performed first, then a regadenoson injection will be given and MR imaging performed with a Gd-BOPTA contrast agent bolus 60-100 seconds later.

Trial Locations (1)

84132

University of Utah, Salt Lake City

All Listed Sponsors
lead

University of Utah

OTHER

NCT01710254 - Regadenoson Stress-MRI to Identify Coronary Artery Disease in Atrial Fibrillation Patients | Biotech Hunter | Biotech Hunter